Lantern Pharma Inc. Launches AI Tool to Predict Cancer Drug Combination Efficacy

Lantern Pharma Inc. (NASDAQ: LTRN) has announced the launch of a new artificial intelligence module within its RADR(R) platform, designed to predict the efficacy of cancer treatment combinations involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). This innovative tool utilizes genomic, transcriptomic, and clinical data to forecast treatment synergy and patient response, supporting the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer.

The development of this predictive algorithm was informed by a comprehensive review of 221 clinical trials, highlighting the potential of non-PARP DDRi combinations with DNA-damaging agents in specific cancer subtypes. With the global market for combination cancer therapies expected to exceed $50 billion by 2030, Lantern Pharma's AI module represents a significant step forward in the field of oncology drug development.

Furthermore, Lantern Pharma is exploring licensing opportunities to commercialize the module for broader use in oncology, potentially transforming the way cancer treatments are developed and personalized for patients. For more information on Lantern Pharma's advancements, visit https://ibn.fm/LTRN.